Effect of Farnesol on Growth, Ergosterol Biosynthesis, and Cell Permeability in Coccidioides posadasii

Coccidioidomycosis is a systemic mycosis caused by the dimorphic fungi Coccidioides spp., primarily affecting individuals in arid regions of the southwestern United States, Mexico, and parts of Central and South America. The disease often presents as a self-limiting pulmonary infection; however, in a subset of patients, it progresses to chronic or disseminated forms that can be life-threatening, particularly in immunocompromised individuals. Current treatment options for chronic and disseminated coccidioidomycosis are limited and frequently prolonged, relying heavily on amphotericin B, itraconazole, and fluconazole. Despite their efficacy, these drugs are associated with significant toxicity—especially nephrotoxicity with amphotericin B—and variable response rates, with only 50–60% of patients responding adequately to azoles. These challenges underscore the urgent need for novel therapeutic agents with improved safety profiles and enhanced antifungal activity.

Farnesol, a natural sesquiterpene metabolite produced by several fungal species including Candida albicans, has emerged as a promising candidate due to its multifaceted biological activities. Originally identified as a quorum-sensing molecule regulating morphological transitions such as yeast-to-hyphal switching and biofilm formation, farnesol also exhibits direct antifungal properties. It interferes with sterol biosynthesis, disrupts membrane integrity, and modulates oxidative stress responses. Recent studies have demonstrated its inhibitory effects against various pathogenic fungi, including Cryptococcus spp. and Candida spp. However, its activity against Coccidioides posadasii—the primary etiological agent of coccidioidomycosis—remains underexplored.

This study aimed to evaluate the in vitro antifungal activity of farnesol alone and in combination with standard antifungals against clinical and environmental strains of C. posadasii. Additionally, we investigated its impact on ergosterol biosynthesis and fungal cell membrane permeability. Using the broth macrodilution method according to CLSI M38-A2 guidelines, we determined the minimum inhibitory concentration (MIC) of farnesol across 18 strains (15 clinical, 3 environmental). Results revealed remarkably low MIC values ranging from 0.00171 to 0.01369 mg/L, indicating potent growth inhibition. When combined with amphotericin B, itraconazole, voriconazole, or caspofungin, farnesol exhibited synergistic interactions, with fractional inhibitory concentration index (FICI) values consistently below 0.5. This suggests that farnesol could serve as an effective adjuvant, potentially reducing the required doses of conventional antifungals and mitigating toxicity.3-(1-Aminoethyl)phenol Biological Activity

Ergosterol quantification assays performed on ten representative strains exposed to subinhibitory concentrations of farnesol showed a significant reduction in intracellular ergosterol levels. This finding supports the hypothesis that farnesol interferes with the sterol biosynthetic pathway, similar to azole antifungals. Furthermore, under conditions of osmotic stress induced by NaCl supplementation in the culture medium, farnesol’s MICs decreased significantly, indicating increased membrane vulnerability.2-sec-Butylphenol Autophagy This effect was not observed with control strains in normal media, reinforcing the notion that farnesol targets fungal membrane integrity, especially when cellular defenses are compromised.PMID:34864059

Collectively, these results demonstrate that farnesol possesses strong in vitro antifungal activity against C. posadasii through multiple mechanisms: inhibition of ergosterol synthesis, disruption of membrane function, and synergistic enhancement of existing antifungals. Given its low cytotoxicity profile reported in prior studies, farnesol emerges as a compelling candidate for further investigation. Future in vivo studies are warranted to assess its efficacy in animal models of coccidioidomycosis, determine pharmacokinetic parameters, and evaluate host-pathogen interactions. If successful, farnesol may represent a new class of adjunctive therapy to improve outcomes in this challenging fungal infection.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com